A Technical Overview of Technegas as a Lung Ventilation Agent

Area of Science:

• Nuclear Medicine
• Radiopharmacology
• Medical Imaging

Background:

• Technegas, a carbon-based nanoparticle developed in Australia in 1984, has been used globally for ventilation imaging since 1986.
• While ^81mKr gas offers ideal ventilation properties, Technegas is preferred in over 60 countries, despite limited U.S. adoption.
• A new U.S. Food and Drug Administration (FDA) application in March 2020 signals potential U.S. market entry.

Purpose of the Study:

• To provide a detailed discussion of Technegas's technical aspects for a U.S. audience.
• To highlight the advantages of Technegas for ventilation imaging, particularly in light of its impending FDA approval.
• To position Technegas as a valuable tool for nuclear medicine departments.

Main Methods:

• Description of Technegas as a simple, versatile system for producing ^99mTc-based ventilation studies.
• Emphasis on the safety features for patients and staff, addressing radiation and biologic risks.
• Discussion of Technegas's role as the gold standard in ventilation/perfusion studies for pulmonary embolism and respiratory pathologies.

Main Results:

• Technegas facilitates high-quality ^99mTc ventilation imaging.
• The system is designed with patient and staff safety as a priority.
• It is established as a gold standard for specific diagnostic applications.

Conclusions:

• Technegas offers a safe and effective method for lung ventilation imaging.
• Impending FDA approval is expected to increase its adoption in the United States.
• Adoption of Technegas is anticipated to improve workflow, safety, and study quality in diagnostic imaging departments.